United States
Germany
Japan
United Kingdom
China
MYO16 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
RNAi
MYO16 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Myo16 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Myo16 - Rat, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
Myo16 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
| Format | Lentiviral plasmids |
| Vector | pGFP-C-shLenti |
Myo16 - Mouse, 4 unique 29mer shRNA constructs in retroviral untagged vector, 5µg of each construct provided
| Format | Retroviral plasmids |
| Vector | pRS |
MYO16 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Myo16 (Mouse) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Myo16 (Rat) - 3 unique 27mer siRNA duplexes - 2 nmol each
| Purity | HPLC purified |
| Number of Transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
